Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Oncopeptides in connection with a directed share issue (5)
Mandate

Vinge advises Oncopeptides in connection with a directed share issue

July 15, 2022 Banking and Finance Capital Markets and Public M&A

The board of directors of Oncopeptides has resolved on a directed new issue of shares, whereby Oncopeptides will raise proceeds of approximately SEK 435,6 million, before issue costs. The price per share in the share issue corresponds to the closing price on Nasdaq Stockholm the day of the share issue.

The share issue is directed to a number of selected international and Swedish reputable investors and life sciences specialist investors.

Oncopeptides is a biotech company focused on research and development of pharmaceuticals for difficult-to-treat haematological diseases. The Company uses its proprietary PDC platform to develop peptide-drug conjugated compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. The company’s shares are admitted to trading on Nasdaq Stockholm.

Vinge’s team has consisted of Dain Hård Nevonen, Linnéa Sellström (capital markets), and Louise Brorsson Salomon, Arvid Weimers and Kamyar Najmi (financing).

Related

Vinge has advised Montrose by Carnegie AB on its application for authorisation to conduct securities business

 Vinge has successfully advised Montrose by Carnegie AB in connection with its application to the Swedish Financial Supervisory Authority for authorisation to conduct securities business. The authorisation was granted by the Swedish Financial Supervisory Authority on 2 July 2026.
August 12, 2026

Vinge advises Mjällby AIF on the transfer of Elliot Stroud to Hull City AFC

 Vinge has advised reigning Allsvenskan champions Mjällby AIF in connection with the transfer of Swedish international Elliot Stroud to Premier League club Hull City AFC.
August 10, 2026

Vinge advises Altor on its public offer for Sleep Cycle

 Snark BidCo, a company controlled by Altor Fund V (No. 1) and Altor Fund V (No. 2) announced a public offer to the shareholders of Sleep Cycle AB to tender all their shares to Snark BidCo. The shares in Sleep Cycle are admitted to trading on Nasdaq Stockholm. After the end of the extended acceptance period, Snark BidCo controls approximately 79.2 percent of the share capital and votes in Sleep Cycle. The total value of the offer was approximately SEK 497 million.
August 07, 2026